Research prototype, not medical advice.

Patisiran (an RNA interference drug that lowers TTR production) improves neuropathy and quality of life in hereditary ATTR (phase 3); approved.

Confidence
Established
Level of evidence
Approved by a health authority
Observed in
Human
Mission
Map of aging (12 hallmarks)
Concepts
Loss of proteostasisPatisiranTransthyretin amyloidosis (ATTR)

What the sources say

Each row is an article. “Supports”: it backs the claim. “Contradicts”: it goes against it. “Qualifies”: it limits it (another species, a weaker effect…).

DirectionSourceWhere in the articleStatus
Supports Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis
Adams et al. · New England Journal of Medicine 2018
— Verified